ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate) – a combination of 2 nucleoside analog HIV-1 reverse transcriptase inhibitors and 1 non-nucleoside HIV-1 reverse transcriptase inhibitor commonly used to treat infection by the human immunodeficiency virus (HIV). FDA approved uses: Atripla is indicated for use alone as a complete regimen or in combination with other antiretroviral agents to treat […]
RITUXAN (rituximab) – a CD20-directed cytolytic antibody indicated for the treatment of patients with rheumatoid arthritis, Granulamatosis, and certain types of leukemias and lymphomas. Rituxan binds specifically to the antigen CD20, a hydrophobic transmembrane protein that is located on pre-B and mature B lymphocytes. The antigen is expressed on 90% of B-cell non=Hodgkins lymphomas (NHL) […]
NEULASTA (pegfilgrastim) – a leukocyte growth factor that is commonly used to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs. FDA approved uses: Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence […]
COPAXONE (glatiramer acetate) – a biologic immune modifier that is commonly used to treat multiple sclerosis (MS). Glatiramer is thought to act by modifying immune processes that believed to be responsible for the pathogenesis of MS. FDA approved uses: Copaxone is indicated for reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis, […]